Open AccessInhibitory Effect of Afatinib on Platelet Activation and Apoptosis
Author(s) -
Hang Cao,
Abdulla Al Mamun Bhuyan,
Anja T. Umbach,
Rosi Bissinger,
Meinrad Gawaz,
Florian Läng
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000484377
Subject(s) - platelet , phosphatidylserine , apoptosis , thrombin , platelet activation , annexin , chemistry , afatinib , microbiology and biotechnology , flow cytometry , biology , immunology , biochemistry , receptor , epidermal growth factor receptor , phospholipid , membrane , erlotinib
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor afatinib is used for the treatment of several malignancies. Afatinib is at least partially effective by triggering apoptosis of tumor cells. Platelets may similarly undergo apoptosis, which is characterized by caspase 3 activation, cell shrinkage and phosphatidylserine translocation. However, an effect of afatinib on platelets has never been reported. The present study explored whether treatment of platelets with afatinib modifies platelet activation and apoptosis in the absence and presence of platelet activators thrombin or collagen related peptide (CRP).